


HDL-CHOLESTEROL DIRECT

REF 1133505 40 mL CONTENTS R1. Reagent 1 x 30 mL R2. Reagent 1 x 10 mL	REF 1133510 320 mL CONTENTS R1. Reagent 3 x 80 mL R2. Reagent 1 x 80 mL	REF 1133515 1000 mL CONTENTS R1. Reagent 3 x 250 mL R2. Reagent 1 x 250 mL	<h2>HDL-CHOLESTEROL DIRECT</h2> <p>Enzymatic colorimetric method</p> <p>FIXED TIME</p>
For <i>in vitro</i> diagnostic use only			

PRINCIPLE

The assay is based on a modified polyvinyl sulfonic acid (PVS) and polyethylene-glycol-methyl ether (PEGME) coupled classic precipitation method with the improvements in using optimized quantities of PVS/PEGME and selected detergents.¹ LDL, VLDL, and chylomicron (CM) react with PVS and PEGME and the reaction results in inaccessibility of LDL, VLDL and CM by cholesterol oxidase (CHOD) and cholesterol esterase (CHER). The enzymes selectively react with HDL to produce H₂O₂ which is detected through a Trinder reaction.



REAGENT COMPOSITION

- R1** **Reagent 1.** MES buffer (pH 6.5), TODB N,N-Bis(4-sulfobutyl)-3-methylaniline, polyvinyl sulfonic acid, polyethylene-glycol-methyl ether, MgCl₂, detergent, EDTA.
- R2** **Reagent 2.** MES buffer (pH 6.5), cholesterol esterase, cholesterol oxidase, peroxidase, 4-aminoantipyrine, detergent.
- CAL** **LDL/HDLc calibrator.** Optative. Ref. 1972005. Concentration value is traceable to NIST SRM 1951b.

STORAGE AND STABILITY

Store at 2-8°C.
 All the kit compounds are stable until the expiry date stated on the label. Do not use reagents over the expiration date.
 Store the vials tightly closed, protected from light and prevented contaminations during the use.

Discard if appear signs of deterioration:

- Presence of particles and turbidity.
- Blank absorbance (A) at 600 nm > 0.080 in 1cm cuvette.

REAGENT PREPARATION

Reagents **R1** and **R2** are ready to use. Stability open on board the analyzer at 2-8°C is of 2 months.

LDL/HDLc calibrator. Lyophilized. Reconstitute contents with distilled water per instructions on vials. Mix gently and let stand for 5 minutes before use. The reconstituted material is stable for 7 days at 2-8°C or for 1 month at -20°C. Discard if it becomes turbid or if there is any evidence of microbial contamination.

The calibrator has been prepared from human serum shown to be negative for HBsAg, HCV and non-reactive for HIV antibodies. Handle with the same precautions used for patient samples.

SAMPLES

Serum, EDTA or heparinized plasma obtained by the patient after an overnight fast. Remove from cells within 3 hours of venipuncture. Samples may be kept at 4-8°C for 2 weeks or at -20°C for 3 months.

INTERFERENCES

- Lipemia (Triglycerides < 12 g/L) does not interfere.
- Bilirubin (< 30 mg/dL) does not interfere.
- Hemoglobin (< 5 mg/dL) does not interfere.
- Ascorbate (< 50 mg/dL) does not interfere.
- Other drugs and substances may interfere.^{5,6}

MATERIALS REQUIRED

- Photometer or spectrophotometer with a thermostatted cell compartment set at 37°C, capable of reading at 600 ± 10 nm.
- Stopwatch, strip-chart recorder or printer.
- Cuvettes with 1-cm pathlength.
- Pipettes to measure reagent and samples.

PROCEDURE

1. Bring reagents and samples to room temperature.
2. Pipette into labelled cuvettes:

Cuvettes	Sample	Calibrator
R1	300 µL	300 µL
Sample	4 µL	-
CAL	-	4 µL

3. Mix, incubate for 5 minutes at 37°C and read (A_{1blank}).
4. Add:

R2	100 µL	100 µL
-----------	--------	--------

5. Mix, incubate for 5 minutes at 37°C and read (A_{2sample}) and (A_{2calibrator}).



CALCULATIONS

$$\Delta A = A_2 - A_1$$

$$\frac{\Delta A_{\text{sample}} - \Delta A_{\text{blank}}}{\Delta A_{\text{calibrator}} - \Delta A_{\text{blank}}} \times C_{\text{calibrator}} = \text{mg/dL HDL-Cholesterol}$$

If results are to be expressed as SI units apply:
 mg/dL x 0.0259 = mmol/L

Samples with concentrations higher than 180 mg/dL should be diluted 1:2 with saline and assayed again. Multiply the results by 2.

REFERENCE VALUES^{2,4}

Clinical values of HDL-Cholesterol used to classify risk groups.

Cholesterol from lipoproteins of high density		RISK
Men	> 55 mg/dL (> 1.42 mmol/L)	Low
	40 - 55 mg/dL (0.90 - 1.42 mmol/L)	Moderate
	< 40 mg/dL (< 1.04 mmol/L)	High
Women	> 65 mg/dL (> 1.68 mmol/L)	Low
	45 - 65 mg/dL (1.16 - 1.68 mmol/L)	Moderate
	< 45 mg/dL (< 1.16 mmol/L)	High

QUALITY CONTROL

The use of a standard to calculate results allows to obtain an accuracy independent of the system or instrument used.

To ensure adequate quality control (QC) each run should include a set of controls (normal and abnormal) with assayed values handled as unknowns.

If the values are found outside of the defined range, check the instrument, reagents and procedure.

Each laboratory should establish its own Quality Control scheme and corrective actions if controls do not meet the acceptable tolerances.

CLINICAL SIGNIFICANCE³

Low HDL-cholesterol is a strong independent predictor of coronary heart disease. In ATP III, low HDL cholesterol is defined categorically as a level < 40 mg/dL (1.04 mmol/L), a change from the level of < 35 mg/dL in ATP II (1993).

Low HDL cholesterol is used as a risk factor to estimate 10-year risk for coronary heart disease, having several causes: elevated triglycerides, overweight and obesity, physical inactivity, and type 2 diabetes. Other causes are, cigarette smoking, very high carbohydrate intakes (> 60% of calories), and certain drugs as anabolic steroids and progestational agents.

ANALYTICAL PERFORMANCE

- **Detection Limit** : 1.06 mg/dL

- **Linearity** : Up to 180 mg/dL

- **Precision**:

mg/dL	Within-run			Between-run		
	Mean	SD	CV%	Mean	SD	CV%
29	0.3	1.0	80	29	0.65	2.3
53	0.41	0.8	80	53	1.36	2.6
90	0.84	0.9	80	90	2.02	2.2
N	80	80	80	80	80	80

- **Sensitivity** : 1.100 mA / mg/dL HDL-Cholesterol.

- **Correlation**: This assay (y) was compared with a similar commercial method (x). The results were:

$$N = 84 \quad r = 0.98$$

The analytical performances have been generated using on automatic instrument. Results may vary depending on the instrument.

NOTES

1. This method may be used with different instruments. Any application to an instrument should be validated to demonstrate that results meet the performance characteristics of the method. It is recommended to validate periodically the instrument. Contact to the distributor for any question on the application method.
2. Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.

REFERENCES

1. Hongbing Xiao Method, composition for determining high density lipoprotein cholesterol. Patent CN 1379235A (2002).
2. Warnick, G. y Wood, P.D., Clin. Chem. 41 : 1427 (1995).
3. SPECIAL REPORT. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III). JAMA. 285 : 2486 (2001).
4. Tietz. N.W. Fundamentals of Clinical Chemistry, p.940. W.B. Saunders Co. Philadelphia, PA. (1987).
5. Friedman y Young. Effects of disease on clinical laboratory tests. 5th ed. AACC (Press 2000).
6. Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000.

B1133-4/1104
R1.ing

